Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
Identification
- Generic Name
- Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
- DrugBank Accession Number
- DB15728
- Background
Umbilical-cord derived MSCs are currently being tested for numerous clinical applications due to their immunosuppressive and anti-inflammatory properties. In comparison to bone-marrow derived MSCs, these cells are more resilient, easier to extract, and generally regarded as less immunogenic. The condition medium (CM) derived from these MSCs has also been implicated in therapeutic properties.
Once MSCs are isolated from the tissue through extraction procedures, they are cultured in the Dulbecco’s Modified Eagle’s Medium (DMEM) to separate soluble factors into the liquid.
Many companies are creating their own version of this medium. One of these companies, Aspire, has created their own product, ACT-20 Conditioned Medium as a product for testing.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Allogeneic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
- Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
- External IDs
- Allogenic Human Umbilical Derived Mesenchymal Stem Cells in Conditioned Media
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
The factors contained in the CM are thought to hold differentiation and therapeutic function, additionally, they may also intensify the positive effects of cell-based therapies. Some of the growth factors and cytokines found include IL-6, VEGF, angiogenin, and IGF-1. Through these factors, the conditioned medium exerts numerous effects, including accelerated wound healing, anti-photo aging, and induced differentiation.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Sriramulu S, Banerjee A, Di Liddo R, Jothimani G, Gopinath M, Murugesan R, Marotta F, Pathak S: Concise Review on Clinical Applications of Conditioned Medium Derived from Human Umbilical Cord-Mesenchymal Stem Cells (UC-MSCs). Int J Hematol Oncol Stem Cell Res. 2018 Jul 1;12(3):230-234. [Article]
- Kim ES, Jeon HB, Lim H, Shin JH, Park SJ, Jo YK, Oh W, Yang YS, Cho DH, Kim JY: Conditioned Media from Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibits Melanogenesis by Promoting Proteasomal Degradation of MITF. PLoS One. 2015 May 29;10(5):e0128078. doi: 10.1371/journal.pone.0128078. eCollection 2015. [Article]
- External Links
- Not Available
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at August 11, 2020 19:06 / Updated at September 21, 2023 13:10